Ocugen, Inc. (OCGN)
Data as of , from SEC Form 4 filings.
See up to 3 months of OCGN. The 7-day demo opens the 1M and 3M ranges and puts OCGN on your watchlist.
Start 7-day demoLatest OCGN insider trades
Shankar Musunuri - OfficerOpen-market sale$445K- Shankar Musunuri - OfficerOpen-market sale$54K
About Ocugen, Inc. (OCGN)
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
- MALVERN, PA
- 116
- 2014
- XNAS
OCGN Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 4 | 1,051,982 | $1.09M |
OCGN insider transactions (Form 4)
2213 Form 4 filings on record, the earliest from Nov 26, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Shankar Musunuri - Officer | Open-market sale | Common Stock | 468,727 | $0.95 footnote F2 | $445K | |
| Shankar Musunuri - Officer | Open-market sale | Common Stock | 57,264 | $0.95 footnote F3 | $54K | |
| ||||||
| Shankar Musunuri - Officer | Open-market sale | Common Stock | 468,727 | $1.12 footnote F2 | $525K | |
| Shankar Musunuri - Officer | Open-market sale | Common Stock | 57,264 | $1.12 footnote F3 | $64K | |
| ||||||
| Treerita Essalima Johnson-Greene - Officer | Open-market purchase | Common Stock | 21,000 | $1.23 | $26K | |
 Uday Kompella - Director | Grant or award | Stock Option (Right to Buy) | 170,100 | $0.00 | - | |
| Satishchandran Chandrasekhar - Director | Grant or award | Stock Option (Right to Buy) | 170,100 | $0.00 | - | |
| Kirsten Castillo - Director | Grant or award | Stock Option (Right to Buy) | 170,100 | $0.00 | - | |
 Junge Zhang - Director | Grant or award | Stock Option (Right to Buy) | 170,100 | $0.00 | - | |
| Blaise Coleman - Director | Grant or award | Stock Option (Right to Buy) | 170,100 | $0.00 | - | |
| Junge Zhang - Director | Option exercise | Common Stock | 15,000 | $0.51 | $8K | |
| Junge Zhang - Director | Option exercise | Common Stock | 112,205 | $0.46 | $52K | |
| Junge Zhang - Director | Option exercise | Common Stock | 66,929 | $1.42 | $95K | |
| Junge Zhang - Director | Option exercise | Option (right to buy) | 15,000 | $0.00 | - | |
| Junge Zhang - Director | Option exercise | Option (right to buy) | 112,205 | $0.00 | - | |
| Junge Zhang - Director | Option exercise | Option (right to buy) | 66,929 | $0.00 | - | |
| Shankar Musunuri - Officer | Grant or award | Common Stock | 3,123,201 | $0.00 | - | |
| Shankar Musunuri - Officer | Grant or award | Option (Right to Buy) | 3,123,201 | $0.00 | - | |
 Ramesh Ramachandran - Officer | Grant or award | Common Stock | 207,300 | $0.00 | - | |
| Ramesh Ramachandran - Officer | Grant or award | Option (Right to Buy) | 310,950 | $0.00 | - | |
| Prabhavathi Fernandes - Director | Open-market purchase | Common Stock | 10,000 | $0.91 | $9K | |
| Kirsten Castillo - Director | Open-market purchase | Common Stock | 25,000 | $0.91 | $23K | |
Recent OCGN Form 144 notices of proposed sale
2An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Shankar Musunuri | Officer | 525,991 | $498K | View on EDGAR | |
| Shankar Musunuri | Officer | 525,991 |
OCGN insider trading FAQ
What is the latest insider trade for OCGN?
Ocugen, Inc. (OCGN) had 2 insider filings in the last 90 days, with the most recent on 2026-10-14. The full record for OCGN runs to 13 Form 4 filings, the earliest from 2024-11-26. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying OCGN stock?
No insider purchases of OCGN were filed in the last 90 days. 3 purchases are on record for this company.
How many insiders are selling OCGN stock?
4 insider sales of OCGN were filed in the last 90 days, totaling $1.09M.
Where can I see OCGN SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects OCGN Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Shankar Musunuri view on EDGAR
- - Shankar Musunuri view on EDGAR
- - Treerita Essalima Johnson-Greene view on EDGAR
- - Uday Kompella view on EDGAR
- - Satishchandran Chandrasekhar view on EDGAR
- - Kirsten Castillo view on EDGAR
- - Junge Zhang view on EDGAR
- - Blaise Coleman view on EDGAR
- - Junge Zhang view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where OCGN's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow OCGN with a 7-day demo
- OCGN on your watchlist
- Every OCGN Form 4 filing on record
- Up to 3 months of OCGN price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
